Bli medlem
Bli medlem

Du är här

2015-03-27

MorphoSys AG: MorphoSys to Host Conference Call on Announcement Regarding the Termination of the Co-development and Co-promotion Agreement for MOR202

MorphoSys AG / MorphoSys to Host Conference Call on Announcement Regarding the
Termination ofthe Co-development and Co-promotion Agreement for MOR202 .
Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is
solely responsible for the content of this announcement.
On 26 March 2015, MorphoSys announced that it has regained rights to MOR202
from Celgene Corporation. The companies have mutually agreed to terminate
their co-development and co-promotion agreement for MOR202. Clinical
development of MOR202, which currently involves a MorphoSys-sponsored phase
1/2a trial in relapsed or refractory multiple myeloma patients, will continue
as planned.

Today, 27 March 2015, at 1:00 p.m. CET (8:00am EDT, 12:00pm GMT), the
Management Board of MorphoSys AG will host a public conference call to
discuss the announcement.

Dial-in number for the Conference Call (listen-only):

Germany: +49 (0) 89 2444 32975

For U.K. residents: +44 (0) 20 3003 2666

For U.S. residents: +1 202 204 1514

A manuscript of the conference will be available
onwww.morphosys.com/conference-callsin due course.

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a
therapeuticpipelineof more than 90 human antibody drug candidates for the
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name
just a few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys,
visithttp://www.morphosys.com.

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®,arYla
®, Ylanthia®and 100 billion high potentials®are registered trademarks of
MorphoSys AG.

Slonomics®is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and
involve risks and uncertainties. Should actual conditions differ from the
Company's assumptions, actual results and actions may differ from those
anticipated. MorphoSys does not intend to update any of these forward-looking
statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG

Dr. Claudia Gutjahr-Löser

Head of Corporate Communications&IR

Mario Brkulj

Associate Director Corporate Communications&IR

Alexandra Goller

Manager Corporate Communications&IR

Jessica Rush

Manager Corporate Communications&IR

Tel: +49 (0) 89 / 899 27-404

investors@morphosys.com

Conference Announcement (PDF)
http://hugin.info/130295/R/1906763/679002.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Globenewswire

HUG#1906763

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.